Biotech | March 06, 2022
Aquestive Therapeutics and Haisco Pharmaceutical partner for riluzole in China.
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Around 85% of ALS patients suffer from a progressive loss of bulbar functionality
Launched in 2020, C-TAP aims to facilitate timely, equitable and affordable access to Covid-19 health products by boosting their production and supply through open, non-exclusive licensing agreements
Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Achieving ML 4 brings Singapore closer to becoming a WHO listed authority, a new scheme that will be operational later this year and will list the world’s regulators of reference
110 BDS graduates admitted in week one of the launch
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Subscribe To Our Newsletter & Stay Updated
